CytomX Therapeutics Income Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	2015 - 2019
Period Ending	Sep '25 Sep 30, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	Dec '20 Dec 31, 2020	2015 - 2019
Revenue	113.63	138.1	101.21	53.16	37.31	68.43	Upgrade
Revenue Growth (YoY)	-10.26%	36.45%	90.38%	42.48%	-45.47%	154.36%	Upgrade
Gross Profit	113.63	138.1	101.21	53.16	37.31	68.43	Upgrade
Selling, General & Admin	28.1	29.73	30.02	40.45	39.16	36.03	Upgrade
Research & Development	62.28	83.38	77.68	106.55	114.19	112.94	Upgrade
Operating Expenses	90.38	113.11	107.7	147	153.35	148.97	Upgrade
Operating Income	23.25	25	-6.48	-93.84	-116.04	-80.54	Upgrade
Interest & Investment Income	5	7.14	9.84	1.68	0.26	1.84	Upgrade
Currency Exchange Gain (Loss)	0.01	-0.04	-0.03	0.34	-0.08	-0.03	Upgrade
EBT Excluding Unusual Items	28.26	32.09	3.32	-91.82	-115.87	-78.73	Upgrade
Merger & Restructuring Charges	-	-	-	-7.5	-	-	Upgrade
Pretax Income	28.26	32.09	3.32	-99.32	-115.87	-78.73	Upgrade
Income Tax Expense	0.25	0.22	3.89	-	-	-13.91	Upgrade
Net Income	28.02	31.87	-0.57	-99.32	-115.87	-64.82	Upgrade
Net Income to Common	28.02	31.87	-0.57	-99.32	-115.87	-64.82	Upgrade
Shares Outstanding (Basic)	117	84	74	66	64	46	Upgrade
Shares Outstanding (Diluted)	118	85	74	66	64	46	Upgrade
Shares Change (YoY)	41.04%	14.82%	12.27%	2.48%	39.01%	1.79%	Upgrade
EPS (Basic)	0.24	0.38	-0.01	-1.51	-1.81	-1.40	Upgrade
EPS (Diluted)	0.24	0.38	-0.01	-1.51	-1.81	-1.40	Upgrade
Free Cash Flow	-72.35	-86.54	-56.88	-112.53	-120.64	2.95	Upgrade
Free Cash Flow Per Share	-0.61	-1.02	-0.77	-1.71	-1.88	0.06	Upgrade
Gross Margin	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	Upgrade
Operating Margin	20.46%	18.10%	-6.41%	-176.50%	-311.00%	-117.70%	Upgrade
Profit Margin	24.66%	23.08%	-0.56%	-186.82%	-310.54%	-94.73%	Upgrade
Free Cash Flow Margin	-63.67%	-62.66%	-56.19%	-211.67%	-323.33%	4.31%	Upgrade
EBITDA	24.53	26.76	-4.31	-91.39	-113.34	-77.97	Upgrade
EBITDA Margin	21.58%	19.38%	-4.26%	-171.91%	-	-113.94%	Upgrade
D&A For EBITDA	1.28	1.77	2.18	2.44	2.71	2.57	Upgrade
EBIT	23.25	25	-6.48	-93.84	-116.04	-80.54	Upgrade
EBIT Margin	20.46%	18.10%	-6.41%	-176.50%	-	-117.70%	Upgrade
Effective Tax Rate	0.87%	0.70%	117.12%	-	-	-	Upgrade

Source: S&P Global Market Intelligence. Standard template. Financial Sources.